References
- CDC . US opioid dispensing rate maps (2022). www.cdc.gov/drugoverdose/rxrate-maps/index.html
- Administration. (2022). Key substance use and mental health indicatorsin the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. (2022). www.samhsa.gov/data/report/2021-nsduh-annual-national-report
- CDC . Provisional drug overdose death counts (2023). www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
- US FDA . Abuse-deterrent opioids – evaluation and labeling: guidance for industry. 1–29 (2015) ( Online). www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling
- Green JL , RobbinsRS , Dailey-GovoniT , ButlerSF. Nonmedical use of Xtampza((R)) ER and other oxycodone medications in adults evaluated for substance abuse treatment: real-world data from the addiction severity index-multimedia version (ASI-MV(R)). J. Pain. Res.14, 1773–1783 (2021).
- Severtson SG , KreiderSED , AmiokaEC , MargolinZR , IwanickiJL , DartRC. Postmarketing analysis of misuse, abuse, and diversion of Xtampza ER. Pain Med.21(12), 3660–3668 (2020).
- Iwanicki JL , SevertsonSG , MargolinZ , DasguptaN , GreenJL , DartRC. Consistency between opioid-related mortality trends derived from poison center and National Vital Statistics System, United States, 2006–2016. Am. J. Public Health108(12), 1639–1645 (2018).
- Researched Abuse, Diversion and Addiction-Related Surveillance . Comparison of population rates between the Drug Abuse Warning Network (DAWN) and the RADARS® System Poison Center Program (2023). www.radars.org/system/publications/2016%204Q%20RADARS%20System%20QTR.pdf
- Fischer LJ , SevertsonSG , GurrolaMC , IwanickiJL , GreenJL , DartRC. Changes in hydrocodone misuse exposures reported to US poison centers following rescheduling in 2014. Subst. Use Misuse57(7), 1097–1103 (2022).
- Reifler LM , DrozD , BaileyJEet al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 13(3), 434–442 (2012).
- Coplan PM , ChilcoatHD , ButlerSFet al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin. Pharmacol. Ther.100(3), 275–286 (2016).
- Severtson SG , BartelsonBB , DavisJMet al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J. Pain14(10), 1122–1130 (2013).
- Coplan PM , KaleH , SandstromL , LandauC , ChilcoatHD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol. Drug Saf.22(12), 1274–1282 (2013).
- Severtson SG , LeLait MC , GreenJL , DartRC. Regional concentrations of Opana® ER abuse before and after introduction of a tamper resistant formulation in 2012. Presented at: The College on Problems of Drug Dependence Annual Scientific Meeting.San Juan, PR, USA (2014).
- Green JL , BucherBartelson B , LeLait MCet al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend.175, 140–145 (2017).
- Choi NG , ChoiBY , DinittoDM , MartiCN , BakerSD. Exposure reasons, other substance use, and medical outcomes of poison control center cases aged 50+ involving opioids, 2015–2020. Clin. Toxicol.60(3), 362–370 (2022).
- Dart RC , SurrattHL , CiceroTJet al. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med.372(3), 241–248 (2015).
- Gummin DD , MowryJB , BeuhlerMCet al. 2021 Annual report of the National Poison Data System((c)) (NPDS) from America’s Poison Centers: 39th Annual Report. Clin. Toxicol.60(12), 1381–1643 (2022).
- Dunn O . Multiple comparisons using rank sums. Technometrics6(3), 241–252 (1964).
- Glickman ME , RaoSR , SchultzMR. False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J. Clin. Epidemiol.67(8), 850–857 (2014).
- Bohnert ASB , IlgenMA. Understanding links among opioid use, overdose, and suicide. N. Engl. J. Med.380(1), 71–79 (2019).
- Gladden RM , O’donnellJ , MattsonCL , SethP. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine – 25 states, July–December 2017 to January–June 2018. MMWR Morb. Mort. Wkly68(34), 737–744 (2019).
- Severtson SG , IwanickiJ , KurtzSED , DartRC. Misclassification may contribute to overestimates of use of specific opioid products. Presented at: The College on Problems of Drug Dependence 81st Annual Scientific Meeting.San Antonio, TX, USA (2019).